HCN Oncology Essentials: ASH Annual Meeting & Exhibition 2021 PreviewDecember 07, 2021 | Oncology Hematology The POLARIX Study: Polatuzumab Vedotin w. Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) vs. R-CHOP Therapy in Patients w. Previously Untreated DLBCL A late-breaking abstract from the ASH Annual Meeting & Exhibition. In this double-blind, placebo-controlled, international study of 879 patients (median age: 65 (range 19–80) years; IPI 3–5 (62%)), the pola-R-CHP combination demonstrated a 27% reduction in the relative risk of disease progression, relapse, or death compared with R-CHOP, with a similar safety profile in the first-line treatment of patients with DLBCL. Read full article Hematology The Longitudinal Dynamics and Natural History of Clonal Hematopoiesis (CH) In this late-breaking abstract from the ASH Annual Meeting & Exhibition, the researches wanted to address the limited understanding of how and when CH develops, what factors govern its behavior, how it interacts with aging, and how these variables relate to malignant progression. Here are the results from analyzing 1,593 blood DNA samples from 385 elderly individuals, each sampled up to 5 times over approximately 13 years. Read full article Hematology Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Subtype-Defining Lesion in Pediatric AML To define the spectrum of alterations common at relapse, the researchers in this study performed integrated profiling of 136 relapsed pediatric AML cases with RNA sequencing (RNA-seq), whole-genome sequencing, and target-capture sequencing. In addition, well-characterized fusion oncoproteins were identified, as were somatic mutations in UBTF (upstream binding transcription factor). See the results from the late-breaking abstract being presented at the ASH Annual Meeting & Exhibition. Read full article Hematology Tisagenlecleucel vs. SOC as 2L Therapy of Primary R/R Aggressive B-Cell NHL: Analysis of the Phase III Belinda Study Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & Exhibition to discover the contributing factors leading to the results, as well as how insights from this study will inform use of cellular treatment in the 2L R/R aNHL setting and the design of future CAR-T trials. Read full article
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH